New 'Tumor-Targeting' radiation tested for tough prostate cancers
NCT ID NCT05983198
Summary
This study is testing a new radioactive drug called [225Ac]Ac-PSMA-R2 in men with advanced prostate cancer that has spread. The main goals are to find a safe dose and see if the drug can shrink tumors. It is for men whose cancer has progressed despite previous hormone therapy and, for some groups, a prior similar radiation treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BAMF Health
Grand Rapids, Michigan, 49503, United States
-
Mayo Clinic Rochester
Rochester, Minnesota, 55905, United States
-
Novartis Investigative Site
Darlinghurst, New South Wales, 2010, Australia
-
Novartis Investigative Site
Melbourne, Victoria, 3004, Australia
-
Novartis Investigative Site
Montreal, Quebec, H2X 1R9, Canada
-
Novartis Investigative Site
Montreal, Quebec, H3T 1E2, Canada
-
Novartis Investigative Site
Dijon, Cote D Or, 21034, France
-
Novartis Investigative Site
Clermont-Ferrand, 63011, France
-
Novartis Investigative Site
Lyon, 69373, France
-
Novartis Investigative Site
Nantes, 44093, France
-
Novartis Investigative Site
Saint-Herblain, 44805, France
-
Novartis Investigative Site
Vandœuvre-lès-Nancy, 54511, France
Conditions
Explore the condition pages connected to this study.